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1. Introduction  
Zonisamide (ZNS, 3-sulfamoylmethyl-1,2-benzisoxazole) was developed by Dainippon 
Pharma (Osaka, Japan: currently Dainippon Sumitomo Pharma) and is currently used as an 
antiepileptic drug (AED) in Japan, South Korea, USA and Europe (Seino, 2004; Seino & 
Leppik, 2007). Indeed, the wide antiepileptic spectrum of ZNS has been established (Brodie, 
2004; Karceski et al., 2005; Seino, 2004; Seino & Leppik, 2007; Willmore, 2004). Several 
clinical studies have also reported the wide clinical spectrum of ZNS against psychiatric and 
non-epileptic neurological disorders, including mood disorders (Ghaemi et al., 2008; 
Ghaemi et al., 2006; Kanba et al., 1994; McElroy et al., 2005), essential tremors (Bermejo, 
2007), and its protective effects against ischemic cerebral damage (Willmore, 2004) and 
Parkinson’s disease (Murata, 2004; Murata et al., 2007). In Japan, ZNS was approved for 
Parkinson’s disease in 2009 by the Ministry of Health, Labor and Welfare. In this chapter, we 
review the dose-dependent effects of ZNS on neurotransmission and differences in the 
mechanisms underlying its antiepileptic and antiparkinsonian effects. 
2. Antiepileptic mechanisms of ZNS 
The major mechanism underlying the antiepileptic effects of ZNS (Rogawski & Porter, 1990) is 
inhibition of the voltage-gated Na+ channel (Rock et al., 1989; Schauf, 1987). However, 
subsequent pharmacological studies have demonstrated that the target molecules of ZNS 
include T-type voltage-sensitive Ca2+ channel (Kito et al., 1996; Suzuki et al., 1992), Ca2+ 
induced Ca2+ releasing system (CICR) (Yamamura et al., 2009b; Yoshida et al., 2005), carbonic 
anhydrase (Yamamura et al., 2009a), redox (Tokumaru et al., 2000; Ueda et al., 2005; Ueda et 
al., 2003), neuronal depolarization-induced glutamate release (Okada et al., 1998; Yoshida et 
al., 2005), enhancement of release of inhibitory neurotransmitters, e.g., GABA (Yoshida et al., 
2005), dopamine and serotonin (Murakami et al., 2001; Okada et al., 1999; Okada et al., 1992; 
Okada et al., 1995) and lack of affinity to GABAA receptor (Rock et al., 1989).  
With regard to its antiparkinsonian action, ZNS enhances both the turnover and release of 
dopamine, and inhibits MAO-B activity and dopaminergic oxidative stress (Asanuma et al., 
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2008; Komatsu et al., 2000; Leppik, 2004; Mori et al., 1998; Murata, 2004; Okada et al., 1992; 
Okada et al., 1995; Ueda et al., 2005). While the typical dose of ZNS is 300 to 600 mg/day for 
patients with epilepsy (Seino et al., 1988), a significant improvement in motor symptoms is 
reported in patients of Parkinson’s disease treated with only 25 to 100 mg/day of ZNS 
(Murata, 2004; Murata et al., 2007). 
 
 
Table 1. Possible antiepileptic mechanism of ZNS 
www.intechopen.com
 
Different Mechanisms Underlying the Antiepileptic and Antiparkinsonian Effects of Zonisamide 
 
25 
2.1 Effects of ZNS on ion channels 
Preclinical studies suggested that ZNS inhibits the propagation of epileptic hyperexcitability 
through neuronal membrane stabilization and prevention of synchronization of firing 
(Macdonald, 2002; Rock et al., 1989; Rogawski & Porter, 1990; Schauf, 1987). Ample evidence 
indicates that the modulation of activities of several types of ion channels is the major 
mechanism of the antiepileptic effect of ZNS (Macdonald, 2002; Rogawski & Porter, 1990; 
Seino & Leppik, 2007).   
2.1.1 Effects of ZNS on voltage-gated Na
+ 
channel  
The antiepileptic effects of ZNS on partial seizures are due to inhibition of voltage-gated 
Na+ channels. In in vitro electrophysiological studies, ZNS reduced sustained repetitive 
firing by inhibiting voltage-gated Na+ channels (Rock et al., 1989; Schauf, 1987). These 
inhibitory effects of ZNS probably increase the threshold of neuronal action potentials and 
lead a shift in the steady-state fast inactivation threshold of voltage-gated Na+ channels 
(Macdonald, 2002; Rogawski & Porter, 1990; Seino & Leppik, 2007). The inhibitory effects of 
ZNS on Na+ currents is probably induced by preferential binding to inactive voltage-gated 
Na+ channels that produces use- and voltage-dependent blockade and slows the rate of 
recovery from inactivation (Macdonald, 2002) 
2.1.2 Effects of ZNS on voltage-sensitive Ca
2+ 
channel  
The role of voltage-sensitive Ca2+ channel in epilepsy is entirely consistent with its ability to 
orchestrate numerous neuronal events thought to be altered in seizures such as 
neurotransmitter release, dendritic physiology, gene expression and notably epileptic 
seizure-induced neuronal apoptosis (Zhang et al., 2000). ZNS inhibits high-threshold 
voltage-sensitive Ca2+ channel (L-type Ca2+ channel)(Kito et al., 1996; Rossier et al., 1996 ). 
ZNS also inhibits low-threshold voltage-sensitive Ca2+ channel (T-type Ca2+ channel) in a 
concentration-dependent manner (Kito et al., 1996; Rossier et al., 1996; Suzuki et al., 1992). 
The T-type Ca2+ channel is activated by small depolarization of the neuronal plasma 
membrane; and the resulting Ca2+ influx generates low threshold spikes that can trigger a 
burst of action potentials mediated by Na+ channels (Perez-Reyes, 2003). Therefore, 
antiepileptic actions of ZNS against childhood absence epilepsy and catastrophic childhood 
epilepsy are mediated through its inhibitory effects on T-type Ca2+ channel (Rogawski & 
Loscher, 2004a, b; White, 1999). 
2.1.3 Effects of ZNS on CICR 
The intraneuronal Ca2+ mobilization comprises both Ca2+ influx via voltage-sensitive Ca2+ 
channels and ligand-gated ion channels, as well as output from intracellular Ca2+ stores 
associated with the endoplasmic reticulum, namely the CICR, which is comprised of the 
ryanodine receptor (RyR) and inositol 1,4,5-trisphosphate receptor (IP3R) (Berridge, 1998). 
Several studies have indicated recently that functional abnormalities of CICR contribute to 
the rise in intraneuronal Ca2+ concentration associated with epileptic seizures (Matsumoto & 
Nagata, 1999; Matsumoto et al., 1996; Mori et al., 2005). Transient up-regulation of both c-
Fos and Ryr-3 gene expression was observed in the hippocampus of the kainate-induced 
epilepsy model (Mori et al., 2005). Antagonists of both RyR and IP3R had no effect on the 
induction or persistence of epileptiform discharges, but both types of antagonists prevent 
seizure-induced neuronal death (Pal et al., 2001; Pelletier et al., 1999). During resting stage, 
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ZNS activates IP3R but has no effect on RyR (Yamamura et al., 2009c; Yoshida et al., 2005). 
Contrary to the resting stage, during neuronal hyperexcitability, ZNS inhibits the activities 
of both IP3R and RyR (Yamamura et al., 2009c; Yoshida et al., 2005). These actions of ZNS 
are similar to other antiepileptic drug, topiramate (Okada et al., 2005).  
2.2 Effects of ZNS on other neuromodulating systems 
2.2.1 Effects of ZNS on the redox system 
Current research associates free radical damage with epilepsy (Komatsu et al 1995; Sudha et 
al 2001), and the use of antioxidants early in the treatment of seizure-related neuronal injury 
is an attractive strategy, since epileptic seizures cause neuronal cell damage through the 
production of free radicals (Komatsu et al., 2000; Sudha et al., 2001). ZNS protects neurons 
against free-radical damage by scavenging the hydroxyl and nitric oxide radicals and such 
action is dose-dependent (Leppik, 2004; Mori et al., 1998; Noda et al., 1999). Especially, ZNS 
provides scavenging effects against cytosolic and plasma membrane-targeting free radicals 
in epileptogenic foci (Komatsu et al., 2000; Tokumaru et al., 2000; Ueda et al., 2005; Ueda et 
al., 2003). The radical scavenging properties operate in not only the ZNS-related 
antiepileptic activity but also its neuroprotective action against hypoxic/ischemic brain 
damage (Hayakawa et al., 1994; Owen et al., 1997).  
2.2.2 Effects of ZNS on carbonic anhydrase 
It was initially thought that the inhibitory effects of ZNS on carbonic anhydrase do not  
contribute to the antiepileptic action of ZNS, since the IC50 value of ZNS is 188 times less 
potent than that of acetazolamide (Masuda & Karasawa, 1993). However, subsequent 
studies demonstrated that different affinities to carbonic anhydrase subtypes (Casini et al., 
2003; Supuran, 2008). The Ki values for ZNS on cytosolic hCAII (35 nM), mitochondrial 
hCAV  (20 nM) and plasma membrane binding hCAIX (5.1 nM) (Casini et al., 2003; Supuran, 
2008) are lower than the therapeutic-relevant plasma concentrations of ZNS (Okada et al., 
1999; Okada et al., 1995; Yamamura et al., 2009a). Activation of GABAA receptor opens its 
Cl− channel, which is permeable to both HCO3− efflux and Cl− influx (Staley et al., 1995). 
Under physiological conditions, the hyperpolarizing action of the Cl− influx abolishes the 
depolarizing effect of HCO3− efflux (Staley et al., 1995). In contrast to physiological 
conditions, continuous neuronal hyperactivation, e.g., epileptic seizure, results in an 
increase in intraneuronal Cl− concentration (Ge et al., 2006; Ge et al., 2007; Okada et al., 
2003). A rise in Cl- concentration in the synaptic active zone stimulates GABAA receptor to 
produce depolarizing action (Ge et al., 2006; Ge et al., 2007). Inhibition of carbonic 
anhydrase reduces intraneuronal HCO3− concentration with enhancement of Na+-
independent Cl−/HCO3− exchange (Leniger et al., 2004). Thus, ZNS prevents the epileptic 
hyperexcitability-induced conversion of GABAA receptor activity from inhibitory to 
excitatory activity (Yamamura et al., 2009a).  
2.3 Effects of ZNS on neurotransmitter system 
The generation of epileptic seizures could be due to a relative imbalance between excitatory 
and inhibitory neurotransmission, resulting in increased neuronal excitability and 
abnormally frequent patterns of discharge (Hirose et al., 2000; Okada et al., 2002). Glutamate 
is one of the main excitatory neurotransmitters, and excessive release of glutamate seems to 
precipitate seizures in epileptic patients and in animal models of epilepsy (Hirose et al., 
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2000; Okada et al., 2002). In contrast to glutamate, various other neurotransmitters, e.g., 
GABA, dopamine, serotonin and acetylcholine, are involve in the regulation of inhibitory 
transmission (Hirose et al., 2000; Okada et al., 2002; Okada et al., 2010).   
2.3.1 Effects of ZNS on glutamatergic system  
Both systemic administration of therapeutically-relevant dose and local perfusion of 
therapeutically-relevant concentration of ZNS reduced depolarization induced glutamate 
release in the hippocampus and frontal cortex (Okada et al., 1998; Yamamura et al., 2009a; 
Yamamura et al., 2009b; Yamamura et al., 2009c; Yoshida et al., 2005). It has been 
demonstrated that continuous stimulation induced by glutamate release has several 
components: (1) a Ca2+-dependent initial rise, which is neuronal activity-independent, (2) 
this initial rise s followed by a series of Ca2+-dependent phasic rises associated with 
neuronal activity, and (3) a small overflow of glutamate that persists in a Ca2+-independent 
manner (Obrenovitch et al., 1993; Obrenovitch et al., 1996; Okada et al., 1998; Zilkha et al., 
1995). Especially, the third component, which is Ca2+ independent and neuronal activity 
independent glutamate release, is probably spreading depression induced release (Okada et 
al., 1998). Therapeutically relevant concentrations of ZNS inhibit these three types of 
glutamate effects in the hippocampus (Okada et al., 1998).  
2.3.2 Effects of ZNS on GABAergic system  
ZNS has dual action against GABAergic transmission; enhancement of GABA release and 
protection against conversion GABAA receptor activity from inhibitory to excitatory action. 
ZNS tends to enhance the inhibitory function of GABAA receptor through interaction at 
allosteric or other binding sites (Mimaki et al., 1988) and GABAergic transmission via down-
regulation of GABA transporter (Ueda et al., 2003). Inhibition of carbonic anhydrase reduces 
intraneuronal HCO3− concentration with enhancement of Na+-independent Cl−/HCO3− 
exchange (Leniger et al., 2004). Although there is no direct evidence that it activates GABAA 
receptor-associated neuronal events, ZNS enhances the Cl− currents associated with GABAA 
receptor (Mimaki et al., 1988). These actions of ZNS are possibly modulated by inhibition of 
carbonic anhydrase activity similar to topiramate (Sills et al., 2000). Both systemic 
administration of therapeutically-relevant dose and local perfusion of therapeutically-
relevant concentration of ZNS increased and decreased the basal and depolarization- 
induced releases of GABA in the hippocampus and frontal cortex, respectively (Okada et al., 
1998; Yamamura et al., 2009a; Yamamura et al., 2009b; Yamamura et al., 2009c; Yoshida et 
al., 2005). Furthermore, the inhibitory interneurons release GABA (Hirose et al., 2000; Okada 
et al., 2002; Staley et al., 1995; Zhu et al., 2008).  
2.3.3 Effects of ZNS on monoamine release  
Systemic administration of ZNS affects monoamine release in the hippocampus, frontal 
cortex and striatum in a biphasic dose-dependent manner (Kawata et al., 1999; Murakami et 
al., 2001; Okada et al., 1999; Okada et al., 1992; Okada et al., 1995; Okada et al., 2002). At 
therapeutically-relevant dose, ZNS increases extracellular levels of monoamines, whereas 
ZNS at supra-therapeutic dose decreases monoamine release (Kawata et al., 1999; Murakami 
et al., 2001; Okada et al., 1999; Okada et al., 1992; Okada et al., 1995; Okada et al., 2002). 
Similar to its effect on the release of monoamines, both acute and chronic administration of 
therapeutically-relevant doses of ZNS enhance the turnover of dopamine and serotonin (i.e., 
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monoamine synthesis) (Okada et al., 1999; Okada et al., 1992; Okada et al., 1995). In 
addition, ZNS inhibits monoamine oxidase activity. These stimulatory effects of ZNS on 
monoaminergic transmission, via enhancement of monoamine synthesis and release with 
inhibition of monoamine degradation, are observed after chronic administration (Okada et 
al., 1999; Okada et al., 1992; Okada et al., 1995).  
3. Antiparkinsonian mechanisms of ZNS 
In an open clinical trial of a combination of ZNS (50-200 mg/day) with antiparkinsonian 
drugs showed lessening of symptoms, wearing off of Parkinson’s disease, and more than 
30% improvement of total score of the Unified Parkinson’s Disease Rating Score up to 3 
years (Murata, 2004; Murata et al., 2001). The addition of ZNS to L-DOPA treatment in 
patients experiencing “wearing-off“ fluctuations resulted in lessening of motor fluctuation 
and significant improvement of the duration, severity, and activities of daily living in “off ” 
time and the score of motor examination. A more recent double blind controlled study from 
Japan demonstrated that the combination of lower than antiepileptically-relevant dose of 
ZNS (25-100 mg/day) and L-DOPA improved all cardinal symptoms of Parkinson’s disease 
(Murata et al., 2007). Based on these clinical evidences, ZNS was released for use in Japan in 
March 2009 as a novel antiparkinsonian agent.  
In a series of studies, we have reported a dose-dependent biphasic action for ZNS on striatal 
dopaminergic system, e.g., ZNS at 25–50 mg/kg (i.p.) increased whereas at 100 mg/kg (i.p.) 
it decreased striatal dopamine release. However, ZNS at lower than antiepileptically-
relevant dose of ZNS failed to modulate striatal dopaminergic transmission (Murakami et 
al., 2001; Okada et al., 1999; Okada et al., 1992; Okada et al., 1995; Yamamura et al., 2009b). 
These results suggest possible differences in the mechanisms of the antiepileptic and 
antiparkinsonian actions of ZNS. In this regard, the mechanism of the antiparkinsonian 
action of ZNS remains poorly understood. 
 
 
Table 2. Possible antiparkinsonian mechanism of ZNS 
3.1 Inhibition of dopamine quinone formation 
Under normal conditions, dopamine is stable in the synaptic vesicle; however, 
administration of L-DOPA to patients with Parkinson’s disease damages the dopaminergic 
neuronal system (Sulzer et al., 2000). In patients with Parkinson’s disease treated with L-
DOPA, a large amount of dopamine remains in the cytosol away from the synaptic vesicle, 
since the damaged dopaminergic system has only a small dopamine pool for storage 
(Asanuma et al., 2008; Asanuma et al., 2003; Ogawa et al., 2005; Sulzer et al., 2000).  
Despite the beneficial effects of L-DOPA, the toxicity of excess L-DOPA and dopamine has 
been well documented in many in vitro and in vivo animal studies using parkinsonian 
models (Asanuma et al., 2008; Asanuma et al., 2003; Ogawa et al., 2005; Sulzer et al., 2000).  
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Free excess dopamine is easily metabolized via type-B monoamine oxidase (MAO-B) or by 
auto-oxidation to produce cytotoxic reactive oxygen species (ROS), and then forms 
neuromelanin (Sulzer et al., 2000). In the oxidation of dopamine by MAO-B, dopamine is 
converted to DOPAC to generate general ROS hydrogen peroxide (Sulzer et al., 2000). 
Conversely, non-enzymatic and spontaneous auto-oxidation of L-DOPA and dopamine 
produces superoxide and reactive quinones, dopamine-quinone and DOPA-quinone, 
(Asanuma et al., 2003; Ogawa et al., 2005; Sulzer et al., 2000; Tse et al., 1976). The highly 
reactive dopamine-quinone or DOPA-quinone itself exerts predominant cytotoxicity in 
dopaminergic neurons and surrounding neurons, since these quinones are generated from 
free cytosolic dopamine away from the synaptic vesicle or from L-DOPA (Sulzer et al., 
2000). 
ZNS prevents dopamine-quinone formation induced by excess amount of cytosolic 
dopamine outside the synaptic vesicles (Asanuma et al., 2008). 
3.2 Enhancement of glial glutathione synthesis 
Glutathione acts as an antioxidant against ROS–induced neurodegeneration. Astrocytes, but 
not neurons, express cystine/glutamate exchange transporter, which takes up cystine, 
reduces it to cysteine, and consequently supplies cysteine, the substrate for glutathione 
synthesis, in neurons. Glutathione synthesis in neurons is dependent on the expression of 
the cystine/glutamate exchange transporter on astrocytes (Shih et al., 2006; Wang & 
Cynader, 2000). Other studies demonstrated that glutathione and its synthesis-related 
molecules provide protection for astrocytes against age-dependent nigrostriatal 
dopaminergic neuro-degeneration (Chinta et al., 2007; Solano et al., 2008). ZNS markedly 
increased glutathione levels by enhancing the astroglial cystine/glutamate exchange 
transporter and astroglial proliferation via S100β production or secretion. ZNS acts as a 
neuroprotectant against oxidative stress and progressive dopaminergic neurodegeneration 
(Asanuma et al., 2010). 
3.3 Enhancement of transmission striato-pallidal indirect pathway 
Parkinson’s disease is characterized neuropathologically by a relative and selective loss of 
dopaminergic projection neurons within the substantia nigra pars compacta (SNc), and the 
formation of cytoplasmic inclusions within many surviving neurons (Gibb, 1991). The 
reduced population of dopaminergic neurons in SNc leads to the development of classical 
symptoms of Parkinson’s disease through functional abnormalities in striatal output 
pathways, which are composed of direct and indirect pathways (Hauber, 1998). In the rat 
brain, the direct pathway is composed of striatal GABAergic neurons, which project to the 
substantia nigra pars reticulata (SNr), a region under dopamine D1 receptor-mediated 
stimulatory regulation (Hauber, 1998). The indirect pathway comprises the striatal 
GABAergic neurons that project to the globus pallidus (GP) and are under dopamine D2 
receptor-mediated inhibitory regulation, the pallidal GABAergic neurons that project to the 
nucleus subthalamicus (STN) and the subthalamic glutamatergic neurons that project to GP 
and SNr (Hauber, 1998). Indeed, depletion of dopaminergic transmission produces over-
inhibition of pallido-subthalamic GABAergic and disinhibition of subthalamonigral 
glutamatergic projections in the indirect pathway (DeLong, 1990; Hauber, 1998). Enkephalin 
is colocalized and acts as cotransmitter with GABA in striatal neurons that project to GP; 
however, enkephalin reduces the GABAergic inhibition in the indirect pathway via 
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inhibition of GABA release (Maneuf et al., 1994). Based on these effects, the δ opioid 
receptor and its endogenous agonist enkephalin have been proposed as a suitable target in 
the symptomatic therapy of Parkinson’s disease (Hille et al., 2001; Maneuf et al., 1994).  
Local administration of antiepileptic-relevant concentrations of ZNS in the striatum 
increases dopamine release, whereas the use of antiparkinsonian-relevant concentration of 
ZNS does not affect striatal dopamine release (Yamamura et al., 2009b). Local 
administration of both antiparkinsonian- and antiepileptic-relevant concentrations of ZNS 
in the striatum reduces the extracellular levels of GABA in STN and glutamate in SNr, but 
decreases extracellular levels of GABA in GP without affecting their level in SNr 
(Yamamura et al., 2009b). These concentration-dependent effects of ZNS on extracellular 
neurotransmitter levels are independent of dopamine and δ2 receptors; however, blockade 
of δ1 receptor inhibited the effects of ZNS (Yamamura et al., 2009b). Activation of δ1 
receptor enhances the effects of ZNS on neurotransmitter level. Based on these results, we 
suggest that ZNS does not affect the direct pathway but inhibits the δ1 receptor-mediated 
indirect pathway.  
4. Conclusion  
It has been well established that ZNS is the first line antiepileptic drug in the treatment of 
partial, absence and generalized epilepsies. In addition, ZNS is a potentially useful agent in 
the treatment of Parkinson’s disease. Its antiepileptic potential has been demonstrated in 
several clinical studies and meta-analysis studies; however, the antiparkinsonian potential 
has been demonstrated in only one randomized, placebo-controlled study. 
The mechanisms of the antiepileptic action of ZNS have been investigated through various 
basic experiments, whereas the antiparkinsonian mechanisms remain to be clarified. 
Interestingly, the dose of ZNS used for the treatment of patients with Parkinson’s disease is 
lower than its therapeutic range against epilepsy. To our knowledge, the pharmacological 
profile within the antiparkinsonian dose has demonstrated only an increase in glutathione 
synthesis and enhancement of transmission through the indirect pathway. Enhancement of 
the indirect pathway is probably involved in the improvement of symptoms of Parkinson’s 
disease. In contrast, activation of glutathione synthesis prevents the progression of 
Parkinson’s disease rather than improves symptoms. Therefore, ZNS likely improves long-
term prognosis. More information is required to clarify the effects of ZNS on long-term 
prognosis of patients with Parkinson’s disease (the long-term efficacy of ZNS).  Based on 
clinical experience in the treatment of epilepsy for more than 20 years in Japan, ZNS is a 
relatively safe and well tolerated drug.  
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